Vertex Beats Q2 Estimates, Raises Revenue Outlook Amid Strong Drug Sales
By John Damon | Just The News Iowa
Vertex Pharmaceuticals reported strong second-quarter results that beat Wall Street expectations, driven by robust sales of its cystic fibrosis drugs and growing contributions from newer treatments. The company also raised its full-year revenue forecast, signaling continued momentum.
For the quarter ended June 30, 2026, Vertex posted non-GAAP earnings of $4.73 per share on revenue of $3.3 billion, topping analyst forecasts of $4.72 per share and $3.22 billion in revenue. Shares slipped slightly in regular trading, closing at $470.72, down 1.34%, and edged lower after hours to $469.19.
CF Franchise Remains Core Growth Driver
The company's cystic fibrosis portfolio remains its primary engine. Global CF revenue rose 11% year over year, with U.S. sales up 9% and international sales up 12%. The next-generation CF treatment Alyftrek crossed $1 billion in revenue in the first half of 2026, reflecting strong uptake among patients switching from older therapies.
Vertex CEO Reshma Kewalramani said the company's goal in cystic fibrosis is to bring patients to carrier levels of sweat chloride. Nearly two-thirds of younger patients achieved sweat chloride levels below 30 millimoles per liter, while more than 75% of patients ages 12 and older reached carrier-range function.
New Products Gaining Traction
Outside CF, Vertex is building a more diversified portfolio. The gene therapy Casgevy generated $76 million in the quarter, while the non-opioid pain medicine Journavx brought in $50 million. Together, the two products are on track to help Vertex achieve its goal of $500 million or more in non-CF revenue this year.
Journavx prescriptions totaled approximately 535,000 in the second quarter, with about 900,000 for the first half of 2026. The drug is now covered by 260 million lives, with 180 million having unrestricted access.
Pipeline Progress and Future Milestones
Vertex continues to advance its pipeline across multiple disease areas. Key upcoming milestones include:
- VX-828 data expected in the second half of 2026
- AMPLIFY results in fall 2026
- Povetacicept regulatory decision in IgA nephropathy on November 30, 2026
- AMPLITUDE interim analysis in early 2027
- Updated type 1 diabetes plans later in 2026
- Closing of the Crinetics acquisition in the third quarter
Financial Strength and Shareholder Returns
Vertex ended the quarter with approximately $13.6 billion in cash and investments. The company used about $455 million to repurchase roughly 1 million shares during the quarter, reflecting its commitment to returning value to shareholders while maintaining flexibility for strategic growth.
The company raised its full-year 2026 revenue guidance to $13.1 billion to $13.2 billion, citing strong first-half results and momentum across the business.
What This Means for Iowa Investors
For Iowa investors, Vertex's performance underscores the strength of the biotechnology sector and the importance of innovation in health care. The company's continued investment in research and development, combined with its expanding product portfolio, positions it for sustained growth. With a market capitalization of $119.3 billion and a P/E ratio of 27.97, Vertex remains a significant player in the pharmaceutical industry.
The company's focus on cystic fibrosis, pain management, and kidney disease aligns with broader health care trends that affect Iowans and Americans nationwide. As Vertex continues to develop new treatments and expand its commercial reach, investors will be watching closely for further developments.